Biotech stocks slumped Wednesday, with Rapport Therapeutics (RAPP), Climb Bio (CLYM) and Cullinan Therapeutics (CGEM) among the hardest-hit names. All three come from the Medical-Development Biotech industry group. This includes more than 500 publicly traded biotech stocks whose companies who have yet to launch a commercial product.
The group fell a collective 4%. It ranks 30th out of 145 groups…
Extract — continue reading at the source.
Related stories
Why is the price of protein powder rising?
Palantir’s stock is heading for its highest close of the year, in a dramatic comeback
The ingredients for a financial reckoning are all in place
Businesses are growing at the fastest pace in over four years. Why war and inflation aren’t slowing the U.S. economy down.
McDonald’s is making a historic bet on chicken — and AI — to bring back customers
Fuel prices keep rising — and so do Democrats’ chances of winning both the House and Senate